▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #670 by analyst upside · 2026-11-14
CRMD
CorMedix Inc.
Healthcare · Market Cap $370M · P/E 2.3x
ANALYST PRICE TARGET
+218.3%
implied upside to consensus target
Current Price $4.66
Consensus Target $14.83
Bull Target $19.0
Bear Target $13.0
Analysts Covering 6
ANALYST CONSENSUS - STRONG BUY
Strong Buy
3
Buy
3
Hold
0
Sell
0
52-Week Low $4.65
52-Week High $13.02
YTD Return -61.7%
FUNDAMENTALS
Market Cap $370M
P/E Ratio (TTM) 2.3x
Forward P/E 13.3x
EPS (TTM) $2.05
PEG Ratio 3.46
Dividend Yield N/A
Revenue (TTM) $412M
Profit Margin 15.5%
52-WEEK RANGE
52-Week Low $4.65
52-Week High $13.02
Current Price $4.66
Bear Target $13.0
Bull Target $19.0
● Now $4.66 ● Target $14.83
TRADING DATA
Avg Volume 1.4M
YTD Return -61.7%
Analyst Count 6
Consensus Strong Buy
Upside to Target +218.3%
Last Updated 2026-11-14

ANALYST SUMMARY

CorMedix Inc. (CRMD) is currently trading at $4.66 with a Wall Street consensus price target of $14.83, implying potential upside of 218.3% over the next 12 months. 6 analysts currently cover CRMD, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $19.0, while the most cautious has a target of $13.0.

CRMD operates in the Healthcare sector with a market capitalisation of $370M. The stock is down 61.7% year-to-date and is currently trading near the lower end of its 52-week range of $4.65 – $13.02.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CYH +17.5%
Community Health Systems, Inc.
$316M · P/E 9.0x · Hold
VMD +30.9%
Viemed Healthcare, Inc.
$347M · P/E 24.1x · Buy
AGEN +301.2%
Agenus Inc.
$305M · P/E 29.3x · Buy
HSTM +28.7%
HealthStream, Inc.
$856M · P/E 40.0x · Underperform
INFU +25.7%
InfuSystem Holdings, Inc.
$295M · P/E 33.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CRMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Needham - Reiterated
Buy → Buy 2026-11-02 20% win rate (5 calls)
Needham reit
Buy → Buy 2026-10-19 20% win rate (5 calls)
Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-14 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-07 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-04-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-04-28 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-04-28 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
15/30
Consensus clarity
4/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →